Clinical Translational Research in Breast Cancer
Research in a Nutshell
Dr Oikonomidou’s group is developing non-invasive analyses of breast cancer in order to understand better the breats cancer biology, identify potential therapeutic targets in cancer (early and advanced) and identify early a patient’s response to treatment.
|Olga Oikonomidou||Senior Clinical Lecturer in Breast Cancer Medicine & Consultant Medical Oncologist Breast Cancer Translational Research Group Leader & Principal Investigator|
|Sana Shabbir||PhD student|
|Fiona Semple||Senior Post Doctoral Fellow|
- Department of Oncology-Pathology, Karolinska Institutet Breast Center, Karolinska University Hospital
- Institute of Biological Chemistry, Biophysics and Bioengineering, Nasmyth Building, Heriot-Watt University
- Centre of Cardiovascular Science, University of Edinburgh
Partners and Funders
- BCI grant (£100,000) September 2019 Co-PI: Genomics of Endocrine Therapy Resistance – Tailoring Treatment using Personalised Genomic Analysis
- Make2ndsCount (£190,000) June 2019 PI: Identification of biomarkers of response to CDK4/6 inhibitors in cfDNA sequential samples from patients with secondary breast cancer. November 2019
- CRUK Early Cancer Detection initiative (£475K) Co-Inv: ‘’ Multiplex methylation analysis of cell-free DNA for early cancer diagnosis. February 2018.
- NIHR National Institute for Health Research £781K (EME) Co-PI: “Cardiac CARE: A multicentre prospective randomised open-label blinded end-point controlled trial of cardiac troponin guided combination angiotensin receptor blockade and beta blocker therapy to prevent cardiac toxicity in anthracycline treated breast cancer patients”, 3.5 years from September 2017.
- Chief Scientist Office Research Grant (£220,883) Co-PI : Novel sample preparation for improved circulating tumour DNA analysis. 3 years from July 2015.
- MRC Confidence in Concept Scheme - Translation of Medical Informatics (£60,000) PI: Bioinformatics analysis of the NEO pilot study. 2 years from May 2014.
- CRUK Grant-Development Fund (£25,000) PI: for ‘’The NEO study: a study of factors predicting response to neoadjuvant chemotherapy in breast cancer patients’’. April 2014.
- University of Edinburgh Internal fund (£40,000) Co-PI: the role of Magnetic Resonance Phosphorous Spectroscopy (31P-MRS) in detecting changes in heart function associated with the use of chemotherapy drugs used to treat breast cancer. December 2014.
Breast cancer, Translational studies, Genomics, Transcriptomics, cfDNA, DNA methylation, Personalised Medicine.
Trascriptomics, ddPCR, Sanger Sequencing.